A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). The authors explained that while molecularly targeted therapies like Bruton ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

This Research Topic is the second volume of the “Unraveling Breast Cancer Complexity: Insights from Single-Cell Sequencing and Spatial Transcriptomics” ...

A new study has given leukemia researchers a powerful new dataset and collection of analytical methods—and a starting point for future research. One common treatment for leukemia is hematopoietic stem ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

As treacherous as it is complex, the tumor microenvironment (TME) is composed of different cell types that produce an abundance of cross-talking molecules, extracellular vesicles, and metabolites. All ...

The tumor microenvironment is a battleground where infiltrating immune cells either subdue or promote a cancer, all while cancer cells try to dampen the body’s defenses. 1,2 Scientists have studied ...

Cancer cells don’t exist in isolation – instead, they live within a complex ecosystem that also includes immune cells, stromal cells, the extracellular matrix, blood vessels and many other factors.

Genetic and cellular screening is essential for understanding specific cell genotypes and phenotypes, offering crucial insights into disease treatment and prognosis. Immunohistochemistry, in ...